IL-13Rα2 UCAR-T + B7-H3 UCAR-T

IL-13Rα2 UCAR-T + B7-H3 UCAR-T is a combination of two allogeneic (universal) chimeric antigen receptor T cell therapies, each engineered to target distinct tumor-associated antigens. The first component, IL-13Rα2 UCAR-T, consists of T cells modified to express a CAR that specifically recognizes the interleukin-13 receptor alpha 2 (IL-13Rα2), which is overexpressed in various solid tumors such as glioblastoma and other aggressive cancers[1][4]. The second component, B7-H3 UCAR-T, targets the immune checkpoint molecule B7-H3 (CD276), another antigen frequently upregulated in multiple malignancies. Both are designed for off-the-shelf use by employing gene editing to reduce immunogenicity and prevent graft-versus-host disease. The mechanism of action involves direct recognition and killing of tumor cells expressing either IL-13Rα2 or B7-H3 through CAR-mediated cytotoxicity. This dual-targeting approach aims to address tumor heterogeneity and reduce the risk of immune escape.